Physician

Celestine Chima Emmanuel Ishiekwene, M.D. MBA

According to 2025 Medicare claims, Celestine Ishiekwene, M.D. MBA (NPI: 1447505243) practices infectious disease in the Longview, TX market, with the plurality of this provider's patient population coming from Gregg, TX. This provider's primary affiliated billing organization is CHRISTUS TRINITY CLINIC (NPI: 1285684225; TIN: 752616977) and primary practice location at 75601-5580. Ishiekwene is affiliated with the CHRISTUS Health Quality Care Alliance (ACO ID: A3029), Genesis Accountable Care Organization, LLC. (ACO ID: A4799), and CVS ACO (ACO ID: A5407), participating under the MSSP model.

Ishiekwene's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 453 traditional Medicare patients, billed 3,172 HCPCS/CPT codes, and received $212,794 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 922 prescription claims across 192 beneficiaries totaling $281,255 in drug costs, led by Daptomycin (Daptomycin). Open Payments data shows 2 records totaling $47. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $21,335 to $212,794. Similarly, Part D prescription costs have moved sharply higher in recent years, from $3,598 to $281,255. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	145	258	$21,335
2018	529	1,369	$101,803
2019	547	1,344	$92,037
2020	351	1,627	$124,345
2021	296	1,680	$123,612
2022	373	2,224	$159,199
2023	417	2,964	$204,810
2024	453	3,172	$212,794

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	16	90	$3,598
2016	11	140	$149,490
2017	36	253	$256,839
2018	88	368	$211,498
2019	96	245	$162,035
2020	36	126	$96,449
2021	58	189	$83,603
2022	69	270	$90,017
2023	135	676	$297,925
2024	192	922	$281,255

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	80	162	$103
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	291	344	$98
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	137	239	$71
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	374	2,111	$59
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	80	96	$50

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Daptomycin	Daptomycin	125	791	$126,851
Ertapenem	Ertapenem Sodium	105	578	$41,724
Oxacillin Sodium	Oxacillin Sodium	55	322	$18,254
Piperacillin-Tazobactam	Piperacillin Sodium/Tazobactam	54	327	$12,267
Ceftriaxone	Ceftriaxone Sodium	96	610	$7,931

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$47	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Celestine Chima Emmanuel Ishiekwene, M.D. MBA?

Tedicare shows public-source Medicare data for Celestine Chima Emmanuel Ishiekwene, M.D. MBA (NPI 1447505243), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Celestine Chima Emmanuel Ishiekwene, M.D. MBA have ACO affiliation data?

Celestine Chima Emmanuel Ishiekwene, M.D. MBA is shown with ACO affiliation data for CHRISTUS Health Quality Care Alliance (MSSP, ACO ID A3029), Genesis Accountable Care Organization, LLC. (MSSP, ACO ID A4799), and CVS ACO (MSSP, ACO ID A5407).

What billing organization is linked to Celestine Chima Emmanuel Ishiekwene, M.D. MBA?

Celestine Chima Emmanuel Ishiekwene, M.D. MBA is linked to CHRISTUS TRINITY CLINIC (billing NPI 1285684225) in the available physician profile data.

Does Celestine Chima Emmanuel Ishiekwene, M.D. MBA have Open Payments data?

Celestine Chima Emmanuel Ishiekwene, M.D. MBA has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.